Fig. 1From: Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case reportIGF-1 (top) and fasting glucose (bottom) levels during the entire clinical follow-up of the patient. LAN: lanreotide autogel; CAB: cabergoline; SUR: surgery (transsphenoidal adenomectomy); LAR: octreotide LAR; PEG: pegvisomant; PAS: pasireotide; w: weekly. All drugs doses are expressed in mgBack to article page